What's Happening?
Boehringer Ingelheim has decided to terminate its collaboration with OSE Immunotherapeutics on a metabolic dysfunction-associated steatohepatitis (MASH) program following disappointing results from a Phase 2 study. The study failed to meet its primary
endpoint, leading to the decision to halt further development in this indication. The partnership, which began in 2018, involved significant financial commitments, including upfront payments and potential milestone payments. Despite the discontinuation of the MASH program, the development of the molecule BI 770371 for cancer treatment will continue. OSE is now redirecting its resources towards other promising projects, including the development of the CD127 blocker lusvertikimab for ulcerative colitis and other conditions.
Why It's Important?
The termination of the MASH program highlights the challenges pharmaceutical companies face in drug development, particularly in complex diseases like MASH. This decision could impact OSE's strategic direction and financial health, as they shift focus to other high-potential assets. For Boehringer Ingelheim, the move allows them to reallocate resources to more promising areas, such as oncology. The broader pharmaceutical industry may view this as a cautionary tale about the risks associated with investing in early-stage drug development without clear efficacy data. Stakeholders, including investors and patients, will be closely watching how OSE manages this transition and whether their new focus areas yield successful outcomes.
What's Next?
OSE plans to advance the development of lusvertikimab, with a subcutaneous formulation expected by 2027 and a Phase 2b/3 trial in ulcerative colitis potentially starting the same year. The company is also exploring applications for lusvertikimab in chronic pouchitis and hidradenitis suppurativa, with initial data anticipated in 2028. Meanwhile, Boehringer Ingelheim will continue its oncology studies with BI 770371. The industry will be monitoring these developments to assess the viability of OSE's new strategic focus and the potential for future collaborations or partnerships.
